SANSURE BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.46 CNY | +1.49% |
|
+11.62% | +4.65% |
| Apr. 26 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 29 | Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84% | MT |
| Sales 2022 | 6.45B 891M | Sales 2023 | 1.01B 139M | Capitalization | 11.19B 1.54B |
|---|---|---|---|---|---|
| Net income 2022 | 1.94B 268M | Net income 2023 | 364M 50.27M | EV / Sales 2022 | 1.1 x |
| Net cash position 2022 | 5.64B 778M | Net cash position 2023 | 4.74B 655M | EV / Sales 2023 | 6.4 x |
| P/E ratio 2022 |
6.63
x | P/E ratio 2023 |
31.5
x | Employees | 2,006 |
| Yield 2022 |
5.91% | Yield 2023 |
2.36% | Free-Float | 47.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.49% | ||
| 1 week | +11.62% | ||
| Current month | +6.01% | ||
| 1 month | +6.01% | ||
| 3 months | +5.46% | ||
| 6 months | +29.90% | ||
| Current year | +4.65% |
1 week
18.36
20.67
1 month
17.9320.67
Current year
16.0822.00
1 year
14.7222.00
3 years
14.7270.80
5 years
14.72105.10
10 years
14.72105.10
| Managers | Title | Age | Since |
|---|---|---|---|
Li Zhong Dai
CEO | Chief Executive Officer | 56 | 08-04-22 |
Wu Tan
CHM | Chairman | 41 | 09-12-31 |
Zhu Peng
DFI | Director of Finance/CFO | 48 | 17-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
You Lin Qiao
BRD | Director/Board Member | 68 | 19-07-07 |
Li Zhong Dai
CEO | Chief Executive Officer | 56 | 08-04-22 |
Xia Lin Yu
BRD | Director/Board Member | 45 | 08-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.04% | 1 M€ | -6.54% | - | |
| 0.12% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 20.46 | +1.49% | 6,087,060 |
| 24-04-29 | 20.16 | +5.72% | 5,752,609 |
| 24-04-26 | 19.07 | +1.44% | 3,634,305 |
| 24-04-25 | 18.8 | +0.53% | 2,832,740 |
| 24-04-24 | 18.7 | +1.08% | 2,807,105 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.65% | 1.62B | |
| -9.59% | 7.67B | |
| -1.20% | 5.26B | |
| +26.10% | 5.36B | |
| +0.02% | 4.57B | |
| -53.02% | 3.15B | |
| +6.42% | 2.59B | |
| -14.95% | 2.06B | |
| -8.29% | 1.79B | |
| +0.42% | 1.74B |
- Stock Market
- Equities
- 688289 Stock
